ReportGem ReportGem

U.S. COMPANY FILING

ASTRAZENECA PLC — Form 6-K filed 2025-09-29

Filed: 2025-09-29Company: ASTRAZENECA PLCTicker: AZNExchange: NYSEForm: 6-KReport period: 2025-09-29SEC accession: 0001104659-25-094039Event: governanceMateriality: 8

Filing text preview

AstraZeneca proposes a Harmonised Listing Structure with a direct listing of shares on the NYSE, replacing the current ADR listing on Nasdaq, alongside existing listings in London and Stockholm. This aims to broaden its US investor base. The company remains UK-incorporated and headquartered. Shareholder approval is required at a General Meeting on 3 November 2025. Effective date expected 2 February 2026, involving termination of the ADR programme and settlement system migration.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2025-09-29ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR2026-07-14 · 6-KUPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL2026-07-09 · 6-KFDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER2026-05-01 · 6-KASTRAZENECA PRICES A $2BN BOND OFFERING2026-02-26 · 6-K20-F2026-02-24 · 20-F